← Eichor
Study identifier: NCT06771544 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Condition: Melanoma · Melanoma Stage III · Melanoma (Skin)  ·  Sponsor: University of California, Irvine

PhasePhase 2
Planned participants14
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.

This description comes directly from the study's public registry record.

Talk to the study team

Chao Family Comprehensive Cancer Center University of California, Irvine  ·  1-877-827-8839  ·  ucstudy@uci.edu

University of California Irvine Medical

Always discuss trial participation with your own doctor first.

Locations (1)

Chao Family Comprehensive Cancer Center University of California, IrvineOrange, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06771544